Verteporfin photodynamic therapy for neovascular age-related ...
Verteporfin photodynamic therapy for neovascular age-related ... Verteporfin photodynamic therapy for neovascular age-related ...
126 Appendix 114. References[1] References from the ‘Treatment of Age-related macular degeneration byphotodynamic Therapy’ (TAP) and ‘Visudyne In Photodynamic therapy’ (VIP)studiesTreatment of age-related macular degeneration with photodynamic therapy (TAP) StudyGroup. Photodynamic therapy of subfoveal choroidal neovascularization in age-relatedmacular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAPreport. Arch Ophthalmol 1999;117:1329-45. (Erratum in: Arch Ophthalmol 2000;118:488.)Bressler NM; Treatment of Age-Related Macular Degeneration with Photodynamic Therapy(TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in agerelatedmacular degeneration with verteporfin: two-year results of 2 randomized clinicaltrials-TAP report 2. Arch Ophthalmol 2001;119:198-207.Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES, et al.;Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) StudyGroup. Verteporfin therapy of subfoveal choroidal neovascularization in patients with agerelatedmacular degeneration: additional information regarding baseline lesion composition'simpact on vision outcomes-TAP report No. 3. Arch Ophthalmol 2002;120:1443-54.Rubin GS, Bressler NM; Treatment of Age-Related Macular Degeneration withPhotodynamic therapy (TAP) study group. Effects of verteporfin therapy on contrast onsensitivity: Results From the Treatment of Age-Related Macular Degeneration WithPhotodynamic Therapy (TAP) investigation-TAP report No 4. Retina 2002;22:536-44.Blumenkranz MS, Bressler NM, Bressler SB, Donati G, Fish GE, Haynes LA, et al.;Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) StudyGroup. Verteporfin therapy for subfoveal choroidal neovascularization in age-related maculardegeneration: three-year results of an open-label extension of 2 randomized clinical trials--TAP Report no. 5. Arch Ophthalmol 2002;120:1307-14.Blinder KJ, Bradley S, Bressler NM, Bressler SB, Donati G, Hao Y, et al.; Treatment of AgerelatedMacular Degeneration with Photodynamic Therapy study group; Verteporfin inPhotodynamic Therapy study group. Effect of lesion size, visual acuity, and lesioncomposition on visual acuity change with and without verteporfin therapy for choroidalneovascularization secondary to age-related macular degeneration: TAP and VIP report no.1. Am J Ophthalmol 2003;136:407-18.Barbazetto I, Burdan A, Bressler NM, Bressler SB, Haynes L, Kapetanios AD, et al.;Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group;Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfovealchoroidal neovascularization with verteporfin: fluorescein angiographic guidelines forevaluation and treatment--TAP and VIP report No. 2. Arch Ophthalmol 2003;121:1253-68.Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, et al.; Treatment ofAge-Related Macular Degeneration with Photodynamic Therapy Study Group; Verteporfin inPhotodynamic Therapy Study Group. Acute severe visual acuity decrease afterphotodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP andVIP report no.3. Am J Ophthalmol 2004;137:683-96.
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 6127Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, et al.;Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) StudyGroup; Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy ofsubfoveal choroidal neovascularization in age-related macular degeneration: meta-analysisof 2-year safety results in three randomized clinical trials: Treatment Of Age-Related MacularDegeneration With Photodynamic Therapy and Verteporfin In Photodynamic Therapy StudyReport no. 4. Retina 2004;24:1-12.Bressler SB, Pieramici DJ, Koester JM, Bressler NM. Natural history of minimally classicsubfoveal choroidal neovascular lesions in the treatment of age-related maculardegeneration with photodynamic therapy (TAP) investigation: outcomes potentially relevantto management--TAP report No. 6. Arch Ophthalmol 2004;122:325-9.[2] National Institute of Clinical ExcellenceTechnology appraisal 68: Full guidance on the use of photodynamic therapy for age-relatedmacular degeneration. 24 Sep 2003. http://www.nice.nhs.uk/pdf/68_PDTGuidance.pdf[3] Other references relating to the Verteporfin Photodynamic TherapyHarding S. Photodynamic therapy in the treatment of subfoveal choroidal neovascularisation.Eye 2001;15:407-12.Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness ofphotodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondaryto age-related macular degeneration. Ophthalmology 2001;108:2051-9.Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. Improvement inquality of life from photodynamic therapy: a Canadian perspective. Can J Ophthalmol2001;36:332-8.Haddad WM, Coscas G, Soubrane G. Eligibility for treatment and angiographic features atthe early stage of exudative age related macular degeneration. Br J Ophthalmol2002;86:663-9.Verteporfin Roundtable 2000 and 2001 Participants; Treatment of age-related maculardegeneration with photodynamic therapy (TAP) study group principal investigators;Verteporfin in photodynamic therapy (VIP) study group principal investigators. Guidelines forusing verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularizationdue to age-related macular degeneration and other causes. Retina 2002;22:6-18.Keam SJ, Scott LJ, Curran MP. Verteporfin: a review of its use in the management ofsubfoveal choroidal neovascularisation. Drugs 2003;63:2521-54.Meads C, Hyde C. Photodynamic therapy with verteporfin is effective, but how big is itseffect? Results of a systematic review. Br J Ophthalmol 2004;88:212-7.Keam SJ, Scott LJ, Curran MP. Spotlight on verteporfin in subfoveal choroidalneovascularisation. Drugs Aging 2004;21:203-9.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State for Health.
- Page 91 and 92: DOI: 10.3310/hta16060Health Technol
- Page 93 and 94: DOI: 10.3310/hta16060Health Technol
- Page 95: DOI: 10.3310/hta16060Health Technol
- Page 98 and 99: 84 References16. Stelmack J. Qualit
- Page 100 and 101: 86 References49. Guymer RH, Chiu AW
- Page 102 and 103: 88 References83. Margrain TH. Minim
- Page 104 and 105: 90 Appendix 1THE VERTEPORFIN PHOTOD
- Page 106 and 107: 92 Appendix 11. Overview of Manual
- Page 108 and 109: 94 Appendix 1And, if also collectin
- Page 110 and 111: 96 Appendix 1more patients in the v
- Page 112 and 113: 98 Appendix 12.4 Limitations of the
- Page 114 and 115: 100 Appendix 1Box 2 Key advantages
- Page 116 and 117: 102 Appendix 14. Study population4.
- Page 118 and 119: 104 Appendix 15. Recruitment to the
- Page 120 and 121: 106 Appendix 16. Background data co
- Page 122 and 123: 108 Appendix 1Table 1: Schedule of
- Page 124 and 125: 110 Appendix 1The Verteporfin Photo
- Page 126 and 127: 112 Appendix 1• Additional clinic
- Page 128 and 129: 114 Appendix 18. Recording adverse
- Page 130 and 131: 116 Appendix 1level of benefit from
- Page 132 and 133: 118 Appendix 1• comparison of num
- Page 134 and 135: 120 Appendix 110.6 Sub-group analys
- Page 136 and 137: 122 Appendix 112. Data issues12.1 D
- Page 138 and 139: 124 Appendix 113. Organisation13.1
- Page 142 and 143: 128 Appendix 1Barnes RM, Gee L, Tay
- Page 144 and 145: 130 Appendix 1Appendix 1: Classifyi
- Page 146 and 147: 132 Appendix 1Liverpool re-treatmen
- Page 148 and 149: 134 Appendix 1Service StructurePlea
- Page 150 and 151: 136 Appendix 1Has your photographer
- Page 152 and 153: 138 Appendix 1There are many differ
- Page 154 and 155: 140 Appendix 1testing on vision tes
- Page 156 and 157: 142 Appendix 1something to do with
- Page 158 and 159: 144 Appendix 1College of Ophthalmol
- Page 160 and 161: 146 Appendix 1Appendix 5:Protocol f
- Page 162 and 163: 148 Appendix 16.2 Subjective Refrac
- Page 164 and 165: 150 Appendix 1• The patient shoul
- Page 166 and 167: 152 Appendix 1Appendix 6:Protocol f
- Page 168 and 169: 154 Appendix 18. It is customary to
- Page 170 and 171: 156 Appendix 1Early or Transit Phas
- Page 172 and 173: 158 Appendix 1
- Page 174 and 175: 160 Appendix 1---------------------
- Page 176 and 177: 162 Appendix 1---------------------
- Page 178 and 179: 164 Appendix 1---------------------
- Page 180 and 181: 166 Appendix 1Appendix 9:Site imple
- Page 182 and 183: 168 Appendix 1Option 2 - units inte
- Page 184 and 185: 170 Appendix 1Dos and Don’tsDosDo
- Page 186 and 187: 172 Appendix 1Resource use question
- Page 188 and 189: 174 Appendix 1Appendix 11: Recommen
DOI: 10.3310/hta16060Health Technology Assessment 2012; Vol. 16: No. 6127Azab M, Benchaboune M, Blinder KJ, Bressler NM, Bressler SB, Gragoudas ES, et al.;Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) StudyGroup; <strong>Verteporfin</strong> in Photodynamic Therapy (VIP) Study Group. <strong>Verteporfin</strong> <strong>therapy</strong> ofsubfoveal choroidal <strong>neovascular</strong>ization in <strong>age</strong>-<strong>related</strong> macular degeneration: meta-analysisof 2-year safety results in three randomized clinical trials: Treatment Of Age-Related MacularDegeneration With Photodynamic Therapy and <strong>Verteporfin</strong> In Photodynamic Therapy StudyReport no. 4. Retina 2004;24:1-12.Bressler SB, Pieramici DJ, Koester JM, Bressler NM. Natural history of minimally classicsubfoveal choroidal <strong>neovascular</strong> lesions in the treatment of <strong>age</strong>-<strong>related</strong> maculardegeneration with <strong>photodynamic</strong> <strong>therapy</strong> (TAP) investigation: outcomes potentially relevantto man<strong>age</strong>ment--TAP report No. 6. Arch Ophthalmol 2004;122:325-9.[2] National Institute of Clinical ExcellenceTechnology appraisal 68: Full guidance on the use of <strong>photodynamic</strong> <strong>therapy</strong> <strong>for</strong> <strong>age</strong>-<strong>related</strong>macular degeneration. 24 Sep 2003. http://www.nice.nhs.uk/pdf/68_PDTGuidance.pdf[3] Other references relating to the <strong>Verteporfin</strong> Photodynamic TherapyHarding S. Photodynamic <strong>therapy</strong> in the treatment of subfoveal choroidal <strong>neovascular</strong>isation.Eye 2001;15:407-12.Sharma S, Brown GC, Brown MM, Hollands H, Shah GK. The cost-effectiveness of<strong>photodynamic</strong> <strong>therapy</strong> <strong>for</strong> fellow eyes with subfoveal choroidal <strong>neovascular</strong>ization secondaryto <strong>age</strong>-<strong>related</strong> macular degeneration. Ophthalmology 2001;108:2051-9.Sharma S, Hollands H, Brown GC, Brown MM, Shah GK, Sharma SM. Improvement inquality of life from <strong>photodynamic</strong> <strong>therapy</strong>: a Canadian perspective. Can J Ophthalmol2001;36:332-8.Haddad WM, Coscas G, Soubrane G. Eligibility <strong>for</strong> treatment and angiographic features atthe early st<strong>age</strong> of exudative <strong>age</strong> <strong>related</strong> macular degeneration. Br J Ophthalmol2002;86:663-9.<strong>Verteporfin</strong> Roundtable 2000 and 2001 Participants; Treatment of <strong>age</strong>-<strong>related</strong> maculardegeneration with <strong>photodynamic</strong> <strong>therapy</strong> (TAP) study group principal investigators;<strong>Verteporfin</strong> in <strong>photodynamic</strong> <strong>therapy</strong> (VIP) study group principal investigators. Guidelines <strong>for</strong>using verteporfin (visudyne) in <strong>photodynamic</strong> <strong>therapy</strong> to treat choroidal <strong>neovascular</strong>izationdue to <strong>age</strong>-<strong>related</strong> macular degeneration and other causes. Retina 2002;22:6-18.Keam SJ, Scott LJ, Curran MP. <strong>Verteporfin</strong>: a review of its use in the man<strong>age</strong>ment ofsubfoveal choroidal <strong>neovascular</strong>isation. Drugs 2003;63:2521-54.Meads C, Hyde C. Photodynamic <strong>therapy</strong> with verteporfin is effective, but how big is itseffect? Results of a systematic review. Br J Ophthalmol 2004;88:212-7.Keam SJ, Scott LJ, Curran MP. Spotlight on verteporfin in subfoveal choroidal<strong>neovascular</strong>isation. Drugs Aging 2004;21:203-9.© Queen’s Printer and Controller of HMSO 2012. This work was produced by Reeves et al. under the terms of a commissioning contract issued by theSecretary of State <strong>for</strong> Health.
Change language